1-15 of 166
Rethinking Cardiovascular Risk: Uncovering the Blind Spots
Conversations in CV Risk AssessmentRethinking Cardiovascular Risk: Uncovering the Blind Spots
Elevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
Conversations in CV Risk AssessmentElevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
Primary Care and Cardiology: Shared Responsibility in Albuminuria Detection
Conversations in CV Risk AssessmentPrimary Care and Cardiology: Shared Responsibility in Albuminuria Detection
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiersSpinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
The Convergence"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
Finerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
Heart MattersFinerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
- advertisement
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
NephrologyIndividualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
NephrologyThe Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Diuretic Response in the ICU: A Practical Predictor of Renal Trajectory
Clinician's RoundtableDiuretic Response in the ICU: A Practical Predictor of Renal Trajectory
- advertisement
AIP Emerges as a Potential Marker for Diabetic Kidney Risk
Clinician's RoundtableAIP Emerges as a Potential Marker for Diabetic Kidney Risk
Beyond Anemia: Why Iron Matters in Every Stage of Chronic Kidney Disease
Clinician's RoundtableBeyond Anemia: Why Iron Matters in Every Stage of Chronic Kidney Disease
Navigating Genetic Testing in Kidney Transplants: Clinical and Ethical Issues
Clinician's RoundtableNavigating Genetic Testing in Kidney Transplants: Clinical and Ethical Issues
